Banco Bilbao Vizcaya Argentaria S.A. lessened its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 52.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,336 shares of the medical research company's stock after selling 4,844 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in IQVIA were worth $762,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after buying an additional 798,534 shares during the period. Northern Trust Corp raised its position in shares of IQVIA by 16.2% during the 4th quarter. Northern Trust Corp now owns 1,791,229 shares of the medical research company's stock valued at $351,994,000 after acquiring an additional 250,141 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of IQVIA by 26.8% in the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company's stock valued at $253,695,000 after purchasing an additional 304,258 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of IQVIA by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company's stock worth $251,852,000 after purchasing an additional 40,699 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of IQVIA by 13.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,393,140 shares of the medical research company's stock worth $273,766,000 after purchasing an additional 167,057 shares during the period. 89.62% of the stock is owned by institutional investors.
IQVIA Stock Performance
Shares of IQV stock opened at $190.9870 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The company's 50 day moving average price is $173.70 and its two-hundred day moving average price is $168.26. The company has a market capitalization of $32.47 billion, a P/E ratio of 27.64, a price-to-earnings-growth ratio of 2.10 and a beta of 1.30.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter in the prior year, the company earned $2.64 earnings per share. The business's quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on IQV shares. Citigroup reissued a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Barclays upped their price target on IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Truist Financial lifted their price objective on shares of IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Evercore ISI upped their target price on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. Finally, JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $228.62.
Read Our Latest Stock Analysis on IQVIA
Insider Activity
In other news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.